Aegis Evaluates Chinese Bio Firms
December 12, 2012 at 09:34 AM EST
Aegis Capital Corporation today initiated coverage of four Chinese biotech and biomedical firms that are expected to perform well in the near future. Aegis initiated a 15-month price target of $12 per share for TrovaGene (Nasdaq: TROV ), which at the time of the report was only valued at $4.61
